Gene · 7980
Papers2,421
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,421
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Reassessing the Role of Tissue Factor Pathway Inhibitor 2 in Neoplastic and Non-Neoplastic Lesions. | Cancers (Basel) | 2025 | 40361374 | PubTator, text mining | PubMed |
| Inhibition of hepatitis C virus replication in HepG2 cells via modulation of the Raf-1 and interferon-alpha signaling pathways by thymoquinone. | Arch Virol | 2025 | 40317342 | PubTator, text mining | PubMed |
| Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance. | Cells | 2025 | 40277888 | PubTator, text mining | PubMed |
| Effect of bone marrow blood versus peripheral blood on the hemostatic balance of osteoblasts and endothelial cells. | Sci Rep | 2025 | 40258877 | PubTator, text mining | PubMed |
| miR-130a-5p/TFPI2 axis promotes invasion of hepatocellular carcinoma by altering epithelial-to-mesenchymal transition. | Discov Oncol | 2025 | 40244374 | PubTator, text mining | PubMed |
| Retraction Note: A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. | Oncogene | 2025 | 40210760 | PubTator, text mining | PubMed |
| Retraction Note: Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas. | Oncogene | 2025 | 40205017 | PubTator, text mining | PubMed |
| Analysis of the clinical application value of cfDNA methylation and fragmentation in early diagnosis of esophageal cancer. | Genomics | 2025 | 40188889 | PubTator, text mining | PubMed |
| Erratum: [Corrigendum] Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer. | Oncol Lett | 2025 | 40144804 | PubTator, text mining | PubMed |
| Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma. | Clin Chim Acta | 2025 | 40024277 | PubTator, text mining | PubMed |
| Assessment of tissue factor pathway inhibitor 2 (TFPI2) as a novel serum marker for malignant tumors of the ovary before and after treatment: A case-control study. | J Obstet Gynaecol Res | 2025 | 39971476 | PubTator, text mining | PubMed |
| Assessment of Biological Age With Conventional Ultrasound Imaging as an Alternative to X-Ray-A Pilot Study in Youth Soccer. | Eur J Sport Sci | 2025 | 39910800 | PubTator, text mining | PubMed |
| Downregulated TFPI2 Accelerates Skin Aging by Repressing the Cell Cycle through Phosphoinositide 3-Kinase/Protein Kinase B/CDC6 Pathway. | J Invest Dermatol | 2025 | 39848565 | PubTator, text mining | PubMed |
| VAMP8 as a biomarker and potential therapeutic target for endothelial cell dysfunction in atherosclerosis. | Gene | 2025 | 39800194 | PubTator, text mining | PubMed |
| Systematic identification of pathological mechanisms, prognostic biomarkers and therapeutic targets by integrating lncRNA expression variation in salivary gland mucoepidermoid carcinoma. | Sci Rep | 2025 | 39794354 | PubTator, text mining | PubMed |
| Olink Profiling of Intestinal Tissue Identifies Novel Biomarkers For Colorectal Cancer. | J Proteome Res | 2025 | 39757570 | PubTator, text mining | PubMed |
| Unlocking regeneration potential: harnessing morphogenic regulators and small peptides for enhanced plant engineering. | Plant J | 2025 | 39658544 | PubTator, text mining | PubMed |
| TFPI2 hypermethylation promotes diabetic atherosclerosis progression through the Ap2α/PPARγ axis. | J Mol Cell Cardiol | 2025 | 39631358 | PubTator, text mining | PubMed |
| APPLICATION OF TFPI2 IN SEPSIS SEVERITY PREDICTION. | Shock | 2025 | 39617416 | PubTator, text mining | PubMed |
| Enhanced radiotherapy susceptibility in NSCLC through palbociclib-mediated PP5 inhibition. | Biochim Biophys Acta Mol Cell Res | 2025 | 39617046 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7980/papers?page=3